Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Iris Melanoma
Extraocular Extension Melanoma
Metastatic Intraocular Melanoma
Stage III Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions: Biological: ziv-aflibercept
Other: pharmacological study

First Posted Date: 2007-03-22

Last Posted Date: 2018-05-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00450255

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Lycopene in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy, no Evidence of Disease
Prostate Cancer

Interventions: Dietary Supplement: lycopene
Other: pharmacological study

First Posted Date: 2007-03-22

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00450957

Locations: 🇺🇸
University of Illinois, Chicago, Illinois, United States

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Radiation: Samarium Sm 153 lexidronam pentasodium
Biological: Sargramostim
Biological: Recombinant vaccinia-TRICOM vaccine
Biological: Recombinant fowlpox-TRICOM vaccine

First Posted Date: 2007-03-22

Last Posted Date: 2017-01-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT00450619

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Safety of Batracylin in Patients With Solid Tumors and Lymphomas

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2007-03-22

Last Posted Date: 2019-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00450502

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Esophageal Cancer in Northeastern Iran

Completed

Conditions: Esophageal Cancer
GI Disease

First Posted Date: 2007-03-22

Last Posted Date: 2025-06-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50045

Registration Number: NCT00450788

Locations: 🇮🇷
Digestive Disease Research Institute, Tehran, Iran, Islamic Republic of

Diabetes in Neuropsychiatric Disorders

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Olanzapine

First Posted Date: 2007-03-13

Last Posted Date: 2014-11-19

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 30

Registration Number: NCT00446992

Locations: 🇪🇸
Unitat Hospitalitzacio - Servei de Psiquiatria G096, Hospital Clinic C/Villarroel, 170, Barcelona, Spain

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Flavopiridol

First Posted Date: 2007-03-09

Last Posted Date: 2018-01-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00445341

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: erlotinib hydrochloride
Drug: sorafenib tosylate
Other: pharmacological study

First Posted Date: 2007-03-09

Last Posted Date: 2016-04-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00445588

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 6 locations

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Terminated

Conditions: Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms

Interventions: Drug: Vandetanib

First Posted Date: 2007-03-09

Last Posted Date: 2012-06-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00445549

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus

Completed

Conditions: Obesity
Overweight
Diabetes Mellitus, Type 2

Interventions: Behavioral: Nutrition counseling
Drug: Metformin
Drug: Insulin
Behavioral: Exercise counseling

First Posted Date: 2007-03-09

Last Posted Date: 2025-06-29

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 82

Registration Number: NCT00445627

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy